ein for presentation outside of the U.S. and Japan only. Not to be reproduced, distributed or excerpt AP2934106 Rev. A 1 Abbott Vascular's Bioresorbable Scaffold Programme, a new paradigm in PCI Richard J. Rapoza, PhD Divisional Vice President of R&D
13
Embed
Information contained herein for presentation outside of the U.S. and Japan only. Not to be reproduced,…
Information contained herein for presentation outside of the U.S. and Japan only. Not to be reproduced, distributed or excerpted. AP Rev. A 3 The Evolution of PCI Treatment Options BenefitsDetrimentsTLR PTCA 1970s Minimally invasive alternative to CABG Excellent long-term durability of results for patients who did well through ~6 months Acute/sub-acute closure High restenosis rates due to negative vessel remodeling 30 – 50% BMS 1980s Eliminated abrupt and sub-acute closure Reduced restenosis rates compared to PTCA Neointimal hyperplasia resulting in in-stent restenosis 15 – 30% DES 2000s Significantly reduced neointimal hyperplasia Reduced restenosis rates compared to BMS Late and very late stent thrombosis Dependence on long-term DAPT 5 – 10% Each of these new technologies addressed the shortcomings of the previous technology, but with their introduction arrived new, significant concerns
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Information contained herein for presentation outside of the U.S. and Japan only. Not to be reproduced, distributed or excerpted. AP2934106 Rev. A
1
Abbott Vascular's Bioresorbable Scaffold Programme, a new
paradigm in PCI
Richard J. Rapoza, PhDDivisional Vice President of R&D
Information contained herein for presentation outside of the U.S. and Japan only. Not to be reproduced, distributed or excerpted. AP2934106 Rev. A
2
MY CONFLICTS OF INTEREST ARE:
Full time employee of Abbott Vascular
Information contained herein for presentation outside of the U.S. and Japan only. Not to be reproduced, distributed or excerpted. AP2934106 Rev. A
3
The Evolution of PCI Treatment OptionsBenefits Detriments TLR
PTCA1970s
• Minimally invasive alternative to CABG• Excellent long-term durability of results for patients who did well through ~6 months
• Acute/sub-acute closure• High restenosis rates due to negative vessel remodeling
30 – 50%
BMS1980s
• Eliminated abrupt and sub-acute closure• Reduced restenosis rates compared to PTCA
• Neointimal hyperplasia resulting in in-stent restenosis
by CABG 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)No new MACE between 6 and 48 months
* One patient withdrew consent and missed the 9, 12, 18 month and 2, 3 and 4 year visits**This patient also underwent a TLR, not qualified as ID-TLR (DS = 42%) followed by post-procedural troponin qualified as NQMI and died from Hodgkin’s disease at 888 days post-procedure
Serruys, PW., AHA 2010.
No thrombosis up to 4 years (all patients off clopidogrel)ABSORB is a trademark of the Abbott Group of Companies
Information contained herein for presentation outside of the U.S. and Japan only. Not to be reproduced, distributed or excerpted. AP2934106 Rev. A
11
ABSORB Cohort B Clinical Results - Intent to treat, Group 1